Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? And what are peptides? 

This week on "The Top Line," Fierce's Zoey Becker, Will Maddox and Kevin Dunleavy chat about some of the biggest recent stories. From a psychedelics acquisition that could spark more movement in the emerging field to an advisory committee meeting on peptides shrouded in political controversy to a lawsuit between the two major obesity drugmakers, we’ll catch you up on the latest developments shaking up the biopharma world.

To learn more about the topics in this episode: 

• ‘A rising tide scenario’: Why other Big Pharmas could follow Lilly into psychedelics 
• UPDATE: Peptides favored on 1st day of closely watched FDA compounding adcomm
• Peptide adcomm Day 2: Emideltide voted down in panel's 1st pushback
• Novo Nordisk files lawsuit accusing rival Eli Lilly of running ‘false and misleading’ GLP-1 ads 
• Novo escalates Lilly false advertising suit with planned bid to halt comparative ads